In a study of patients with EGFR-mutant lung cancer who developed acquired resistance to erlotinib or gefitinib, rapid disease progression was observed after the discontinuation of these tyrosine kinase inhibitors (TKIs) during a clinical trial washout period. The gene discussed is EGFR; the disease is lung carcinoma.